Wang Wei-Jie, Chang Chen-Hung, Sun Mao-Feng, Hsu Sheng-Feng, Weng Ching-Sung
Department of Biomedical Engineering, Chung Yuan Christian University, Chungli, Taiwan; Division of Nephrology, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Healthy and Welfare, Taoyuan, Taiwan.
Department of Pharmacy, Taoyuan General Hospital, Ministry of Healthy and Welfare, Taoyuan, Taiwan.
PLoS One. 2014 Apr 22;9(4):e93447. doi: 10.1371/journal.pone.0093447. eCollection 2014.
Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature. In the present study, we investigate the deleterious effects of IS on proximal tubular cells and the protective role of DPP-4 inhibitor. Human kidney 2 (HK-2) cells were exposed to IS in the presence or absence of DPP-4 inhibitor. Effects of DPP-4 inhibitor on viability of HK-2 cells were determined by MTT assay. Reactive oxygen species (ROS) production was examined using fluorescent microscopy. Levels of cleaved caspase-3, transforming growth factor-beta (TGF-β), α-smooth muscle actin (α-SMA) and NF-kappaB p65 and phosphorylation of AKT and extracellular signal-regulated kinase (ERK) were detected by immunoblotting. Production of ROS and level of cleaved caspase-3 were increased by IS in a dose-dependent manner. The phosphorylation of AKT and ERK p65 were decreased alongside activation of NF-κB. Expression of TGF-β and α-SMA, were upregulated in IS-treated HK-2 cells. Treatment with DPP-4 inhibitor resulted in a significant increase in cell viability and a decrease of ROS production in IS-treated HK-2 cells. DPP-4 inhibitor restored IS-induced deactivations of AKT and ERK and inhibited activation of NF-κB in IS-treated HK-2 cells. Moreover, DPP-4 inhibitor could also attenuate IS-induced up-regulation of TGF-β and α-SMA expression. These findings suggest that DPP-4 inhibitor possesses anti-apoptotic activity to ameliorate the IS-induced renal damage, which may be partly attributed to regulating ROS/p38MAPK/ERK and PI3K-AKT pathways as well as downstream NF-κB signaling pathway.
糖尿病肾病是慢性肾脏病(CKD)的常见病因。二肽基肽酶-4(DPP-4)抑制剂具有改善肾功能和肾微血管的能力。在本研究中,我们探究了高糖对近端肾小管细胞的有害作用以及DPP-4抑制剂的保护作用。将人肾2(HK-2)细胞置于有或无DPP-4抑制剂的环境中,使其暴露于高糖环境。通过MTT法测定DPP-4抑制剂对HK-2细胞活力的影响。使用荧光显微镜检查活性氧(ROS)的产生。通过免疫印迹法检测裂解的半胱天冬酶-3、转化生长因子-β(TGF-β)、α-平滑肌肌动蛋白(α-SMA)和核因子κB p65的水平以及AKT和细胞外信号调节激酶(ERK)的磷酸化水平。高糖以剂量依赖的方式增加了ROS的产生和裂解的半胱天冬酶-3的水平。随着核因子κB的激活,AKT和ERK p65的磷酸化水平降低。在高糖处理的HK-2细胞中,TGF-β和α-SMA的表达上调。用DPP-4抑制剂处理导致高糖处理的HK-2细胞的细胞活力显著增加,ROS产生减少。DPP-4抑制剂恢复了高糖诱导的HK-2细胞中AKT和ERK的失活,并抑制了核因子κB的激活。此外,DPP-4抑制剂还可以减弱高糖诱导的TGF-β和α-SMA表达上调。这些发现表明,DPP-4抑制剂具有抗凋亡活性,可改善高糖诱导的肾损伤,这可能部分归因于调节ROS/p38丝裂原活化蛋白激酶/ERK和磷脂酰肌醇-3激酶- AKT途径以及下游核因子κB信号通路。